Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

ORION B

ORNBV.HEFI0009014377NASDAQ HelsinkiFIEUR
Stock price
ORION B
Loading chart...

Coverage

Latest articles

U.S. FDA approves new indication for Orion-Bayer prostate cancer drug
8 Jun 2025, 20:27ORNBV.HENASDAQ Helsinki

Filings

Recent filings

FilingDate
224,000 Orion A-shares converted into B-22 Oct 2003
Orion?s Simdax will wait for the final s2 Oct 2003
Noiro deal closed1 Oct 2003
150,000 Orion A-shares converted into B-10 Sept 2003
*CONVERSION OF A-SHARE INTO B-SHARE: ORI10 Sept 2003
CapMan to acquire cosmetics unit Noiro f4 Sept 2003
Orion Group Interim Report 1-6/20036 Aug 2003
*CONVERSION OF A-SHARE INTO B-SHARE: ORI1 Aug 2003
Search

Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).

  • Previous
  • 1
  • 2
  • Next
100,000 ORION A-SHARES CONVERTED INTO B-
1 Aug 2003
Orion Pharma?s co-determination process17 Jul 2003
Review in Germany for Orion Pharma´s lev10 Jul 2003
300 ORION A-SHARES CONVERTED INTO B-SHAR7 Jul 2003
  • Previous
  • 1
  • More pages
  • 90
  • 91
  • 92
  • More pages
  • 95
  • Next
Company
ORION B
ORNBV.HENASDAQ Helsinki
Website: Unavailable
Coverage
7
Filings
1,130